OTC: MEOBF - Mesoblast Limited

Yield per half year: +68.54%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Mesoblast Limited


About Mesoblast Limited

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

more details
The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

ISIN AU000000MSB8
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.mesoblast.com
Цена ао 1.37
Change price per day: 0% (1.5)
Change price per week: +9.49% (1.37)
Change price per month: +9.49% (1.37)
Change price per 3 month: -40% (2.5)
Change price per half year: +68.54% (0.89)
Change price per year: +150% (0.6)
Change price per 3 year: +74.42% (0.86)
Change price per 5 year: +3.45% (1.45)
Change price per year to date: +45.63% (1.03)

Underestimation

Title Value Grade
P/S 108.67 1
P/BV 1.34 9
P/E 0 0
EV/EBITDA -11.11 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -13.14 0
ROE, % -17.91 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.89 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -81.67 0
Yield Ebitda, % -16.68 0
Yield EPS, % -39.52 0
Total: 0.4

Institutions Volume Share, %
Legato Capital Management LLC 47380 0.01



Head Job title Payment Year of birth
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director 757k 1957 (68 years)
Dr. Eric A. Rose M.D. Chief Medical Officer & Executive Director 640.92k 1951 (74 years)
Mr. Andrew Chaponnel B.Com. Interim Chief Finance Officer N/A
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons) General Counsel & Corporate Executive N/A 1968 (57 years)
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders N/A
Mr. Michael Schuster BSc, M.B.A., MS Head of Pharma Partnering N/A 1977 (48 years)
Ms. Geraldine Storton B.Sc., M.B.A., MMS Head of Regulatory Affairs & Quality Management N/A
Mr. Justin Horst B.S. Head of Manufacturing N/A
Dr. Paul J. Simmons BSc, Ph.D. Scientific Advisor to the Chief Executive Officer 1959 (66 years)
Dr. Fiona See Ph.D. Senior VP & Head of Translational Research

Address: Australia, Melbourne. VIC, 55 Collins Street - open in Google maps, open in Yandex maps
Website: https://www.mesoblast.com